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Abstract
Background: Molluscum contagiosum is a non-severe pediatric viral infection. Because it is highly contagious and
current treatments have negative aesthetic and psychological effects, we want to test an alternative treatment in
the primary care setting, consisting of two different concentrations of potassium hydroxide solution.
Methods/design: The study design is a double-blind, randomized clinical trial, using three types of topical treatment.
The treatment consist of daily applications of potassium hydroxide (KOH) in aqueous solution at 10% and 15%
concentration, and a placebo administered in the control group. Four follow-up visits (at 15, 30, 45 and 60 days) are
planned to evaluate treatment effectiveness and patient tolerance.
The main outcome measure of the trial will be the healing rate, defined as lesion disappearance in the affected zones
after the topic application of the experimental treatment. Secondary measures will be the principal characteristics and
evolution of the affected zone (surface area, number of lesions, size and density of lesions), treatment tolerance
(hyperpigmentation, itching, burning, pain), recurrence rate and the natural evolution of lesions in the control group.
Discussion: KOH can potentially be an effective and safe treatment for MC in primary care, and can also reduce
referrals to dermatologists and hospital pediatric departments. In addition, KOH may be a valid and less expensive
alternative to current invasive treatments (surgical excision).
Trial Registration: ClinicalTrials.gov: NCT01348386
Background
Molluscum contagiosum (MC) is a viral infection of the
skin [1] produced by a member of the Poxvirus family, the
genus Molluscipoxvirus [2]. The symptoms are the
appearance of pearly, usually umbilicated papulae. The
lesions are completely asymptomatic and can affect any
part of the body, usually affecting the thorax or lower
extremities. They usually appear asymmetrically in pre-
viously injured zones (wounds or atopic dermatitis).
Transmission requires direct contact with the infected
host or contaminated fomites. MC frequently affects
children using community swimming pools or siblings
using the same washing sponges or towels [1-5]. The per-
iod of incubation usually oscillates between three and
twelve weeks. Clinical diagnosis is based on the detection
of the characteristic appearance of lesions. Differential
diagnosis includes folliculitis, follicular hyperkeratosis,
viral verrucas and insect bites. Lesions cause intense feel-
ings of embarrassment not only to parents but also to chil-
dren, which sometimes result in school absenteeism and
curtailed activities. The natural history of MC is sponta-
neous regression within six to eighteen months. However,
because it is highly contagious, new lesions from the incu-
bating virus may appear later. There is considerable debate
as to whether it is necessary to treat the infection. The* Correspondence: icruz.lleida.ics@gencat.cat1Primary Care Research Institute IDIAP Jordi Gol, Catalan Institute of Health.
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aesthetic or psychotherapeutic effects of treatment need to
be evaluated, as well the ease of transmission of the virus.
Treatment consists of different methods to destroy
infected tissue together with the virus. These can be:
crude/bloody (curettage, electrocoagulation, clamping,
etc.), excessive (oral cimetidine, oral isotretinoin), or topi-
cal therapies (salicylic acid, tretinoin or potassium hydro-
xide) [6]. Since 1999, some studies have been published
that satisfactorily tested the use of potassium hydroxide
(KOH) [2,7-9] in different concentrations, and imiquimod
[10]. However, none of these were tested in a standard
pediatric primary care clinic.
Four published studies were found in a clinical biblio-
graphic search. They all concluded that KOH solution is
an effective and safe treatment for MC. A notable hetero-
geneity existed among study methodologies, with different
KOH concentrations used for treatment and/or studies
lacking a control group.
Only one study was designed as a clinical trial, the
others were descriptive designs. All the studies were done
in the context of medical specialties other than pediatrics.
The present study will be conducted in a primary care
setting, as the point of first contact within the National
Health Service (NHS). The aim is to assess the efficacy of
topical KOH treatment in 10% and 15% aqueous concen-
trations, versus a control (placebo) group in a pediatric
clinic in a primary care center (PCC) in Lleida (Spain).
A randomized clinical trial (RCT) design has been
chosen, with the objective of providing the maximum
level of evidence. The treatment will be administered to
three groups - one control and two treatment groups.
This design will compare both treatment groups to the
control group as well as compare the efficacy of the dif-
ferences doses.
We hypothesize that the daily application of KOH treat-
ment for MC is safe and affective in pediatric patients.
Our bibliographic research has identified a paper [7] that
estimates a 20% rate of successful resolution with placebo
treatment and a 70% success rate with KOH treatment,
with a mean treatment period of 54 days. Another study
[8] without a control group and twice daily applications of
10% KOH reported 32 successful resolutions of 35 cases
during a six month period.
This trial has been approved by the Ethical Committee





Evaluate the efficacy (disappearance of lesions) of treat-
ing MC with daily topical applications of KOH (in con-
centrations of 10% and 15%).
1.2 Secondary objectives
- To evaluate reductions in the number, size and
density of MC lesions in affected areas.
- To evaluate the time lapsed between treatment
application and cure (disappearance of the lesions).
- To evaluate tolerance to the treatment.
- To describe the natural evolution of the infection
with respect to the number, size and density of lesions
in affected areas, based on findings in the control
group.
- To compare the differences in efficacy of and toler-
ance to treatment in the three study groups.
Trial design
1.1 Summary of trial design
The study will be a double blind clinical trial with random
treatment allocation. Patients will be randomized into
three parallel treatment arms. Treatment will consist of
the application of topical 10% or 15% KOH in an aqueous
solution for the two treatment groups, compared to a pla-
cebo-treated control group.
A total of five appointments are planned, one baseline
and four follow-up visits. Screening will be done during
the baseline visit to verify that all patients fulfill the inclu-
sion and exclusion criteria, and have signed a written
consent form, in addition to recording sociodemographic
variables and a clinical history.
The efficacy of and tolerance to the treatment, as well
as the appearance of new lesions, concomitant treatments
and adverse affects will be evaluated in the follow-up
visits.
During the baseline visit, the patient will be diagnosed
and essential information will be recorded (inclusion/
exclusion criteria, sociodemographic variables and clini-
cal assessment). All valid/evaluable patients will be
assigned a randomization code, up to a maximum of 60
patients who fulfill the inclusion/exclusion criteria.
Neither the patient, their parents, nor the pediatrician
will know to which group the patient has been assigned.
Four follow-up visits are planned, at 15, 30, 45 and 60
days (± 3 days) from baseline. Each visit will include a
clinical assessment, where the appearance of new lesions
will be recorded. The efficacy of treatment and the toler-
ance of treated lesions since the last visit will be studied.
A photograph of the affected area will be taken. If the
patient misses the follow-up visit, compliance will be
noted in the completion worksheet (which will be filled
out in all remaining cases at 60-day follow-up). The ran-
domization code will be revealed if the attending physi-
cian believes this to be appropriate. In this case the
patient will be removed from the study, filling out the
completion worksheet.
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1.2 Description of the measures taken to minimize/avoid
bias
1.2.1 Randomization and codebreaking Randomization
will be centralized at the Pharmacy Department of the
hospital of reference, the Arnau de Vilanova University
Hospital (HUAV).
Patients will be randomly allocated to one of the study
groups. Randomization will increase the probability of
distributing patients to the three groups homogenously.
1.2.2 Blinding The vials of solution to be studied will
be prepared as follow:
- KOH 10%: 10 grams of KOH dissolved in purified
water, 100 ml
- KOH 15%: 15 grams of KOH dissolved in purified
water, 100 ml
- Placebo: 100 milliliters of saline solution
The vials will be indistinguishable, regardless of con-
tent, and will be stored at room temperature. A mask
and gloves are required for preparing the solutions.
1.2.3 Other measures taken to minimize/avoid bias
HOMOGENEOUS APPLICATION: Each patient will
receive a bottle of the solution assigned (identical bottles),
depending on their randomization code. The parents/
guardians of the patient will be shown how to apply the
solution to the lesions, and written instructions will be
provided, as follows: the treatment should be applied once
per day with a cotton swab soaked in the solution, unless
the lesion shows signs of INFLAMMATION OR IRRITA-
TION, at which point the TREATMENT SHOULD BE
STOPPED (parents should write down the date in order
to inform the physician at the next follow-up visit).
1.3 Primary and secondary endpoints/outcome measures
Efficacy will be assessed in each of the areas detected in
the previous visit. If there are new areas affected, they will
be evaluated at the next visit (a description of the new
lesion will be recorded in the topographic section of the
patients record).
The principle efficacy variable (primary endpoint) will
be calculated for each of the affected areas, as an indica-
tor variable: (1. There is a lesion in the area/0. No lesion
in the area) at 60 days from baseline. Each patient will be
considered cured if they have no lesions in any of the
treated areas.
Secondary efficacy variables (secondary endpoints) will
be calculated for each location as follows:
- Number of lesions.
- Extent of area affected.
- Mean size of lesions.
○ < 0.5 cm.
○ 0.5 cm. - 1 cm.
○ > 1 cm.
- Efficacy of method: Ordinal scale with five
categories.
○ Worsening (net increase in number of lesions
or growth of existing ones).
○ No changes (no modifications to the lesion).
○ Slight improvement (disappearance of up to
50% of lesions).
○ Moderate improvement (disappearance of more
than 50% of lesions).
○ Cure (complete disappearance of lesions) (pri-
mary endpoint).
- Digital photograph.
- Lesion density*: Number of lesions/Extent of
affected area
NOTE: If the parents locate new lesions between visits
they should NOT treat them until the physician has
clinically evaluated their topography.
1.4. Study population
The reference population will be pediatric patients trea-
ted in primary care with a clinical diagnosis of MC.
1.4.1. Inclusion criteria - Who are diagnosed with a
MC infection (clinical diagnosis).
- Who are between the ages of two and six.
- Whose parents or guardians have provided written
informed consent for participation.
1.4.2. Exclusion criteria - Immunocompromised patient
(congenital or acquired).
- Patient has received other topical treatment within
the last month.
- Patient has lesions on face, neck or genital area.
- Patient who, in the view of the attending physician,
will not comply with treatment and/or scheduled
visits.
1.5 Informed consent
In accordance with Spanish law, parents/guardians must
personally sign and date the latest approved version of
the informed consent form before any study specific
procedures are performed.
Written and verbal versions of the Participant Informa-
tion Sheet and the Informed Consent Form will be pre-
sented to the participants (parents/guardians), detailing
no less than: the exact nature of the study; the implica-
tions and constraints of the protocol; the known side
effects and any risks involved in taking part. It will be
clearly stated that the participant is free to withdraw
from the study at any time for any reason without preju-
dice to future care, and with no obligation to provide the
reason for withdrawal.
The participant will be allowed as much time as they
wish to consider the information, and the opportunity
to question the Investigator, their physician or other
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independent parties to decide whether they will partici-
pate in the study. Written informed consent will then
be obtained by means of the participant’s dated signa-
ture and the dated signature of the person who pre-
sented and obtained the informed consent. The person
who obtained the consent must be suitably qualified and
experienced, and have been authorized to do so by the
Principal Investigator. A copy of the signed ICF will be
given to the participants. The original signed form will
be retained at the study site.
1.6 Screening and eligibility assessment
All parents/guardians of patients diagnosed with MC will
be provided the necessary written information for study
enrollment (information sheet) as well as clarification of
any questions they may have. Once the patient has been
determined to be valid (fulfillment of inclusion/exclusion
criteria and written informed consent), they will be
assigned a randomization code. The baseline visit will be
done and then the patient will be scheduled for the next
visit. Each parent/guardian will receive precise instructions
for how to apply the treatment and will receive a vial of
their designated treatment solution coded with the
patient’s number. The patient will be scheduled for the
four follow-up visits at 15, 30, 45 and 60 days from the
first treatment application.
1.7 End of trial assessment
Each study participant can leave the study for two rea-
sons:
1) Loss to follow-up (before the end of follow-up
protocol, without successful treatment).
a. Lack of efficacy.
b. Choice of the patient.
c. Adverse effects.
d. Loss to follow-up (missing scheduled visits).
e. Breaking the blind.
f. Other.
2) Completion of follow-up.
g. Attended all scheduled visits
h. Success of treatment
A completion form should be filled out for all
patients, whether they have finished the study or not.
1.8. Statistical methods and sample size
1.8.1. Statistical analysis The statistical analysis will be
carried out on several different samples of the study popu-
lation. The valid or valuable patient group is defined as
those patients that fulfill all the inclusion criteria, none of
the exclusion criteria, whose parents have provided con-
sent for their participation and who have been assigned a
treatment (randomized code). The safety sample is defined
as the group of valid patients who have received treatment
in the study at least once, whether or not its effectiveness
has been assessed (who came to at least one follow-up
visit). The intention to treat (ITT) sample is defined as the
group of valid patients who have received treatment at
least once and who have been assessed for its effectiveness
at least once. The per protocol (PP) sample is defined as
the group of patients that make up the ITT sample, have
been assessed for efficacy and have not violated the proto-
col in any of the following ways:
- Violation of blinding.
- Greater than 10% missed treatments.
- Loss to follow-up by missing a scheduled visit.
The unit of analysis is the patient. Nevertheless, each
patient can present multiple affected areas. An area is con-
sidered to be a set of lesions whose perimeter does not
coincide with another affected area, with a single area
being possible. No more than 15 affected areas per patient
are expected.
A descriptive analysis of all the variables collected will
be done, expressing quantitative variables as means,
medians, minimums, maximums and standard deviations
(SD), and categorical variables as frequencies and
percentages.
The homogeneity of the study groups with respect to
the following baseline parameters will be compared:
Demographic variables
Initial topography
Clinical history of associated diseases
History of treatments received (> 1 month)
To determine the existence of an association between a
group and secondary efficacy variables at each period of
follow-up, the single-factor ANOVA test will be used for
quantitative variables (extent, number of lesions, etc.) and
the chi-squared test will be used for categorical variables
(cure).
In the case that the ANOVA cannot be used because
a quantitative parameter does not fulfill the application
criteria (non-normality/heteroscedasticity) the data will
be transformed (logarithmic) from the original para-
meter, or a non-parametric analog test (Kruskal-Wallis)
will be used. In all 2 × 2 comparisons (Group I, II vs.
Placebo), the significance level will be adjusted for mul-
tiple comparisons.
The evolution of the quantitative efficacy parameters
will also be assessed, by group, for the different time
periods, using a repeated measures analysis.
The relationship between the baseline variables and the
efficacy variables will be assessed at the end of the study,
and in the case that an association is found, a multivari-
ate analysis will be carried out to assess possible con-
founding factors of the group effect on adjusted efficacy:
a multiple regression analysis will be used in the case of
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quantitative efficacy variables and a multinomial regres-
sion will be used in the case of qualitative variables.
The time from treatment to cure will be calculated as
the difference between the date of first treatment and the
disappearance of lesions or the end of the study (treatment
initiation). Survival tables and the Kaplan-Meier statistic
will be calculated to compare cure times between the dif-
ferent treatment groups. In the case that associations are
found between efficacy variables and baseline conditions, a
Cox proportional risk model will be adjusted.
Data analysis will be by ITT, by protocol and by safety
sample.
In all cases a p-value below 0.05 will be considered
significant.
Data will be analyzed using the statistical package “R":
http://www.r-project.org.
1.8.2. Sample size calculation The calculation of the
sample size takes as its primary outcome treatment effi-
cacy - the rate of complete elimination of MC at the
final follow-up visit (60 days), as specified in a published
clinical trial [7].
Based on this clinical trial, we expect a 20% cure rate in
the control group and a 70% cure rate in one of the
experimental treatment groups. To be able to detect these
differences with a chi-squared test of two independent
samples with a power of 80% at the 5% significance level,
and with an estimated follow-up loss rate of 20%, there
must be 20 patients per group.
1.9. Quality control and quality assurance
In order to ensure the Quality of the data the delegated
organization will:
• Perform regular monitoring according to ICH GCP
guidelines. Data will be evaluated for compliance
with the protocol and accuracy in relation to source
documents. Monitors will verify that the clinical trial
is conducted and data are generated, documented
and reported in compliance with the protocol and
the applicable and local regulatory requirements.
• Provide instructions and training to the sites
involved in the trial.
• Review the CRF data.
• Detail of any other steps taken to ensure research
quality.
Discussion
Currently, there is no satisfactory treatment for the
rapid and non-invasive treatment of MC lesions, so
pediatricians normally allow the infection to run its
course, with duration of between six months and a year.
This situation imposes considerable limitations on the
patient’s lifestyle, especially regarding the use of public
facilities (gyms, pools) due to the elevated infectivity of
the virus, and psychological and social effects especially
in children.
KOH may be a good therapeutic alternative if it is
effective, easy to apply, can be self-administered, has
minimal side effects and is inexpensive. The few pub-
lished studies on the subject do not provide definitive
evidence about KOH as a treatment for MC, given that
these studies have not compared different solution con-
centrations and placebo.
The results of our clinical trial will make it possible to
definitively assess all these aspects of this treatment.
Furthermore, conducting the study in a pediatric pri-
mary care setting, the gateway to the Spanish national
health system, makes it possible to evaluate the utility of
the treatment at the primary care level, addressing the
majority of cases that could benefit from this treatment
while also decreasing referrals to hospital specialists.
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